Barriers, facilitators and needs to deprescribe benzodiazepines and other sedatives in older adults: a mixed methods study of primary care provider perspectives.

Orlando Hürlimann, Daphne Alers, Noël Hauri, Pascal Leist, Claudio Schneider, Lucy Bolt, Nicolas Rodondi, Carole E Aubert
Author Information
  1. Orlando Hürlimann: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland.
  2. Daphne Alers: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland.
  3. Noël Hauri: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland.
  4. Pascal Leist: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland.
  5. Claudio Schneider: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland.
  6. Lucy Bolt: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland.
  7. Nicolas Rodondi: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland.
  8. Carole E Aubert: Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-Von-Krauchthal Weg 7, Bern, 3010, Switzerland. caroleelodie.aubert@insel.ch. ORCID

Abstract

BACKGROUND: Benzodiazepines and other sedative hypnotic drugs (BSHs) are frequently prescribed for sleep problems, but cause substantial adverse effects, particularly in older adults. Improving knowledge on barriers, facilitators and needs of primary care providers (PCPs) to BSH deprescribing could help reduce BSH use and thus negative effects.
METHODS: We conducted a mixed methods study (February-May 2023) including a survey, semi-structured interviews and focus groups with PCPs in Switzerland. We assessed barriers, facilitators and needs of PCPs to BSH deprescribing. Quantitative data were analyzed descriptively, qualitative data deductively and inductively using the Theoretical Domain Framework (TDF). Quantitative and qualitative data were integrated using meta-interferences.
RESULTS: The survey was completed by 126 PCPs (53% female) and 16 PCPs participated to a focus group or individual interview. The main barriers to BSH deprescribing included patient and PCP lack of knowledge on BSH effects and side effects, lack of PCP education on treatment of sleep problems and BSH deprescribing, patient lack of motivation, PCP lack of time, limited access to cognitive behavioral therapy for insomnia and absence of public dialogue on BSHs. Facilitators included informing on side effects to motivate patients to discontinue BSHs and start of deprescribing during a hospitalization. Main PCP needs were practical recommendations for pharmacological and non-pharmacological treatment of sleep problems and deprescribing schemes. Patient brochures were wished by 69% of PCPs. PCPs suggested the brochures to contain explanations about risks and benefits of BSHs, sleep hygiene and sleep physiology, alternative treatments, discontinuation process and tapering schemes.
CONCLUSION: The barriers and facilitators as well as PCP needs and opinions on patient material we identified can be used to develop PCP training and material on BSH deprescribing, which could help reduce the inappropriate use of BSHs for sleep problems.

Keywords

References

  1. Healthc Policy. 2019 May;14(4):39-51 [PMID: 31322113]
  2. BMJ Open. 2023 Feb 22;13(2):e066234 [PMID: 36813499]
  3. Metabolites. 2021 Apr 20;11(4): [PMID: 33923956]
  4. Ther Adv Drug Saf. 2018 Oct 20;9(12):687-698 [PMID: 30546863]
  5. Lancet. 2007 Oct 20;370(9596):1453-7 [PMID: 18064739]
  6. BMC Health Serv Res. 2020 Sep 29;20(1):902 [PMID: 32993650]
  7. Res Social Adm Pharm. 2022 Apr;18(4):2691-2694 [PMID: 34229951]
  8. Ther Adv Drug Saf. 2020 Mar 18;11:2042098620909610 [PMID: 32215198]
  9. Can Med Educ J. 2023 Jun 27;14(3):41-74 [PMID: 37465741]
  10. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081 [PMID: 37139824]
  11. CMAJ. 2000 Jan 25;162(2):225-33 [PMID: 10674059]
  12. Implement Sci. 2022 Jul 8;17(1):41 [PMID: 35804428]
  13. Health Syst Transit. 2020 Dec;22(4):1-441 [PMID: 33527901]
  14. J Hosp Med. 2017 May;12(5):310-316 [PMID: 28459898]
  15. BMJ Open. 2020 Jan 6;10(1):e031156 [PMID: 31911512]
  16. Health Expect. 2017 Aug;20(4):531-542 [PMID: 27669682]
  17. J Sleep Res. 2023 Dec;32(6):e14035 [PMID: 38016484]
  18. Drugs R D. 2017 Dec;17(4):493-507 [PMID: 28865038]
  19. Epidemiol Psychiatr Sci. 2023 Feb 20;32:e12 [PMID: 36803918]
  20. Sleep Med Rev. 2015 Feb;19:17-28 [PMID: 25104471]
  21. JAMA Intern Med. 2023 Mar 1;183(3):223-231 [PMID: 36745422]
  22. Healthc Q. 2015;18(1):11-3 [PMID: 26168384]
  23. Eur J Clin Pharmacol. 2017 Aug;73(8):927-935 [PMID: 28456823]
  24. Drugs Aging. 2022 Dec;39(12):935-947 [PMID: 36409404]
  25. Drugs Aging. 2015 Apr;32(4):305-14 [PMID: 25825121]
  26. Curr Sleep Med Rep. 2017;3(2):48-56 [PMID: 28553574]
  27. JAMA Intern Med. 2014 Jun;174(6):890-8 [PMID: 24733354]
  28. Br J Clin Pharmacol. 2015 Dec;80(6):1254-68 [PMID: 27006985]
  29. Implement Sci Commun. 2020 Nov 30;1(1):107 [PMID: 33292865]
  30. Implement Sci. 2017 Jun 21;12(1):77 [PMID: 28637486]
  31. Adv Pharmacol Sci. 2012;2012:416864 [PMID: 22536226]
  32. Br J Gen Pract. 2010 Apr;60(573):e156-62 [PMID: 20353661]
  33. Clin Ther. 2016 Nov;38(11):2340-2372 [PMID: 27751669]
  34. Med Access Point Care. 2020 Jun 3;4:2399202620922507 [PMID: 36204093]

Grants

  1. grant agreement No 101057123/HORIZON EUROPE European Research Council
  2. contract No 22.00116/Swiss State Secretariat for Education, Research and Innovation (SERI)
  3. Ambizione Grant PZ00P3_201672/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

MeSH Term

Humans
Female
Male
Deprescriptions
Hypnotics and Sedatives
Aged
Benzodiazepines
Middle Aged
Switzerland
Primary Health Care
Attitude of Health Personnel
Adult
Focus Groups
Surveys and Questionnaires
Physicians, Primary Care

Chemicals

Hypnotics and Sedatives
Benzodiazepines

Word Cloud

Created with Highcharts 10.0.0PCPsBSHdeprescribingsleepPCPBSHseffectsneedsproblemsbarriersfacilitatorslackcaremethodsdatapatientolderadultsknowledgeprimaryhelpreduceusemixedstudysurveyfocusQuantitativequalitativeusingincludedsidetreatmentschemesbrochuresmaterialBACKGROUND:BenzodiazepinessedativehypnoticdrugsfrequentlyprescribedcausesubstantialadverseparticularlyImprovingprovidersthusnegativeMETHODS:conductedFebruary-May2023includingsemi-structuredinterviewsgroupsSwitzerlandassessedanalyzeddescriptivelydeductivelyinductivelyTheoreticalDomainFrameworkTDFintegratedmeta-interferencesRESULTS:completed12653%female16participatedgroupindividualinterviewmaineducationmotivationtimelimitedaccesscognitivebehavioraltherapyinsomniaabsencepublicdialogueFacilitatorsinformingmotivatepatientsdiscontinuestarthospitalizationMainpracticalrecommendationspharmacologicalnon-pharmacologicalPatientwished69%suggestedcontainexplanationsrisksbenefitshygienephysiologyalternativetreatmentsdiscontinuationprocesstaperingCONCLUSION:wellopinionsidentifiedcanuseddeveloptraininginappropriateBarriersdeprescribebenzodiazepinessedativesadults:providerperspectivesBenzodiazepineDeprescribingMixedOlderPrimaryQualitativeSedativeSleepdisorder

Similar Articles

Cited By